Simulations Plus Reports Q1 Revenue of $18.4M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Reports Q1 revenue $18.4M, consensus $18.06M. "We met our first quarter revenue guidance and delivered strong performance in our services segment, driven primarily by significant growth in commercialization offerings and modest gains in development projects," said Shawn O'Connor, CEO of Simulations Plus. "In software, the expected decrease in clinical operations and development revenue was only partially offset by an increase in discovery solutions."
Get Free Real-Time Notifications for Any Stock
Monitor tickers like SLP with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on SLP
Wall Street analysts forecast SLP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLP is 19.00 USD with a low forecast of 19.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 18.630
Low
19.00
Averages
19.00
High
19.00
Current: 18.630
Low
19.00
Averages
19.00
High
19.00
About SLP
Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Company’s business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rosen Law Firm Investigates Securities Claims Against Simulations Plus
- Securities Claim Investigation: The Rosen Law Firm is investigating potential securities claims against Simulations Plus (NASDAQ: SLP) for allegedly issuing misleading business information, indicating significant legal risks for the company.
- Underperformance Report: Simulations Plus reported third-quarter 2025 sales of $20.4 million, a 10% year-over-year increase, but fell short of the $20.9 million consensus estimate, highlighting the company's weakening performance and declining market confidence.
- Stock Price Plunge: Following the disappointing earnings report on July 15, 2025, Simulations Plus's stock plummeted by 25.75%, reflecting investor concerns about the company's future outlook and the severity of market reactions.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit, allowing investors to participate in claims without upfront costs, emphasizing the importance of legal support for investor rights and the necessity of addressing potential losses.
Continue Reading
Rosen Law Firm Investigates Simulations Plus for Potential Securities Fraud
- Securities Fraud Investigation: Rosen Law Firm is investigating potential securities claims against Simulations Plus (NASDAQ: SLP) for possibly issuing misleading business information, highlighting serious concerns about the company's transparency.
- Stock Price Plunge: On July 15, 2025, Simulations Plus's stock fell 25.75% after reporting third-quarter sales of $20.4 million, which missed the consensus estimate of $20.9 million, reflecting market pessimism about the company's future outlook.
- Class Action Preparation: The Rosen Law Firm is preparing a class action for affected investors, promising compensation without upfront fees, demonstrating a strong commitment to protecting investor rights.
- Firm's Track Record: The Rosen Law Firm recovered over $438 million for investors in 2019 and was ranked as a leader in securities class actions in 2017, showcasing its extensive experience and success in handling such cases.
Continue Reading